Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
8
×
clinical trials
fda
8
×
life sciences
national blog main
eli lilly
indiana blog main
indiana top stories
amgen
boston blog main
san francisco blog main
san francisco top stories
boston top stories
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
teva pharmaceutical
boulder/denver blog main
boulder/denver top stories
calcitonin gene-related peptide
chronic migraine
detroit blog main
detroit top stories
migraine research foundation
national
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
drugs
episodic migraine
eptinezumab
erenumab
europe blog main
What
approval
8
×
drug
fda
won
developed
migraine
new
class
eli
lilly
medicines
amgen
approved
decades
friday
late
marketing
nod
oral
pain
starts
wins
acute
addresses
agency
aimmune
allergy
amgen’s
announced
arguments
awarded
bid
big
blueprint
boehringer
cancer
candidate
candidates
carries
causes
Language
unset
Current search:
approval
×
biotech
×
fda
×
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines